F8 and hemophilia A: FVIII in the form of recombinant or virus‐inactivated plasma‐derived clotting factor concentrate is a well‐established treatment for hemophilia A.5Prophylactic FVIII replacement therapy, that is, regular rather than episodic administration, is the standard of care in patients with severe hemophilia A and some patients with moderate disease,5 providing safe and effective prevention of bleeding and preservation of joint health.14